Welcome to our dedicated page for RETINALGENIX TECHNOLOGIES news (Ticker: RTGN), a resource for investors and traders seeking the latest updates and insights on RETINALGENIX TECHNOLOGIES stock.
RetinalGenix Technologies develops ultra-high-resolution retinal imaging technology combined with genetic testing and advanced analytics for ophthalmic screening, monitoring, pharmacogenetic mapping, and early disease detection. Company updates commonly address the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform, non-invasive retinal imaging, biomarker research, and the use of retinal data in oculomics for ocular and systemic disease applications.
Recurring developments include research collaborations in proteomics and genotyping, laboratory-services support for genetic and retinal health screening, patent activity for home and remote ocular monitoring, and work tied to conditions such as age-related macular degeneration, glaucoma, diabetic retinopathy, Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative or systemic disorders.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
RetinalGeniX Technologies (RTGN) will present at the Emerging Growth Conference on October 26, 2022, at 1:00 PM Eastern. The 30-minute presentation will be led by Jerry Katzman, the company's CEO, highlighting its mission to prevent blindness through innovative retinal screening and home monitoring. Additionally, the company aims to diagnose systemic diseases, including heart disease and Alzheimer’s, via genetic mapping. Attendees can register for live participation or access an archived webcast post-event.
RetinalGenix Technologies (OTCQB:RTGN) announced the appointment of Dr. Vinay Mehindru to its Board of Directors, aimed at enhancing initiatives for population health management and supporting the company's planned upgrade from OTCBQB to NASDAQ.
Dr. Mehindru brings over 25 years of healthcare expertise, holding leadership roles that integrate clinical and financial operations. His experience includes serving as Chief Medical Officer and building extensive physician networks.
RetinalGenix anticipates his contributions will improve the efficiency and effectiveness of its health screening technologies.
RetinalGeniX Technologies has acquired DNA/GPS Inc., a pharmacogenetics firm, enhancing its capabilities in retinal imaging and genetic mapping. This acquisition aims to revolutionize the diagnosis of systemic diseases like heart disease and Alzheimer’s by allowing healthcare providers to conduct tests at primary care centers, significantly reducing costs compared to traditional methods. The platform is expected to enable early detection and interventions, focusing on patients with genetic predispositions to various diseases, with industry expertise led by Dr. Larry Perich.
RetinalGeniX Technologies, Inc. (OTCQB: RTGN) has officially commenced trading on the OTCQB Venture Market. The company's mission focuses on preventing blindness through high-resolution retinal screening and patient home monitoring. It has launched two innovative products: the RetinalCam™ Home Monitoring System for real-time access, and the RetinalGeniX Imaging System (RIS) for affordable retinal screening without dilation. With diabetes affecting millions and an anticipated increase in cases, RetinalGeniX aims to address the shortage of eyecare professionals and enhance telehealth capabilities.